1318MO First-in-human Study of ABBV-637, an EGFR-targeting BCL-XL–inhibiting Antibody-Drug Conjugate Combined with Osimertinib (OSI) in Relapsed/refractory, EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Annals of oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined